Targeting angiogenesis by inhibiting FN1 binding to αvβ3 inhibits tumor angiogenesis and tumor growth in teratocarcinoma and in the ccRCC cell line 786-O (40). This evidence concerns the gene FN1 and nonpapillary renal cell carcinoma.